Saturday 17 October 2026
Export RKDA’s income statement to Excel — free account
Arcadia Biosciences, Inc.
RKDA Consumer Defensive Packaged Foods
Arcadia Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.9 million, down 3.71% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 35.9% and free cash flow grew 82.1%, each against the same quarter a year earlier.
0.16
0.04
−20.00%
Follow RKDA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.43 | 0.60 | 0.56 | 0.92 | |
P/FCF ratio |
0.62 | 1.83 | 2.51 | 0.00 | |
P/Operating CF |
(6.38) | (2.62) | (3.15) | (18.46) | |
P/B ratio |
3.22 | 1.00 | 0.65 | 0.87 | |
Price to Tangible BV |
3.43 | 1.01 | 0.66 | 0.88 | |
EV/Sales |
(0.43) | (0.15) | (0.36) | (0.20) | |
EV/EBITDA |
0.54 | 0.19 | 0.72 | 0.32 | |
EV/Operating CF |
0.80 | 0.17 | 0.37 | 0.17 | |
EV/FCF |
(0.62) | (0.47) | (1.61) | 0.18 | |
Quick Ratio |
2.88 | 3.04 | 2.42 | 2.94 | |
Current Ratio |
3.49 | 3.79 | 3.09 | 3.67 | |
Net Debt/EBITDA |
8.42 | 4.82 | 3.32 | 5.14 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.69 | 0.52 | 0.48 | 0.43 | |
Operating CF/Net income |
0.05 | 0.25 | 0.64 | (0.30) | |
Capex/Depreciation |
0.00 | 0.00 | 375.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
78.10% | 107.18% | 174.25% | 120.58% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.00 | |
Share Based Compensation of Revenue |
0.97% | 1.36% | 1.89% | 4.07% | |
Graham Net Nets |
0.24 | 0.95 | 1.46 | 1.11 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(669.12%) | (414.49%) | (86.36%) | (106.95%) | |
Free Cash Flow Yield |
161.26% | 54.55% | 39.84% | (121.62%) | |
Revenue per Share |
0.48 | 0.53 | 0.66 | 0.95 | |
Operating CF per Share |
(0.11) | (0.53) | (0.63) | (0.19) | |
Capex per Share |
0.00 | 0.00 | 0.55 | 0.00 | |
Free Cash Flow per Share |
(0.11) | (0.53) | (0.08) | (0.19) | |
Cash per Share |
1.40 | 1.79 | 3.34 | 4.31 | |
Shareholders Equity per Share |
0.21 | 1.39 | 3.03 | 3.98 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.21 | 1.39 | 3.03 | 3.98 | |
Free Cash Flow |
(0.32) | (1.10) | (0.11) | (0.26) | |
Working Capital |
4.09 | 3.80 | 4.30 | 6.10 | |
Capital Expenditures |
— | — | 0.75 | — | |
Net Current Asset Value |
0.48 | 2.73 | 3.95 | 5.25 | |
EV/EBIT |
0.53 | 0.19 | 0.70 | 0.30 | |
Capex to Sales |
0.00 | 0.00 | (0.83) | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.91 | 1.02 | 0.80 | 0.86 | |
Average Payables |
1.47 | 1.50 | 1.95 | 1.85 | |
Average Inventory |
1.21 | 1.06 | 1.06 | 1.15 | |
Average Assets |
6.84 | 9.16 | 10.03 | 11.91 | |
Average Common Equity |
2.58 | 5.90 | 5.18 | 7.80 |
Columns are period end dates